Celldex Therapeutics (CLDX)
Celldex Therapeutics Receivables Turnover: 49.90
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CLDX Receivables Turnover Rankings
| Overall | 94th percentile | 195 of 3458 |
| Sector | 97th percentile | 10 of 391 in Healthcare |
| Industry | 92nd percentile | 1 of 13 in Diagnostic Substances |
CLDX Receivables Turnover Range, Past 5 Years
| Minimum | -7.548 | Sep 2007 |
| Maximum | 160.26 | Sep 2011 |
| Average | 31.01 |
About Receivables Turnover Ratio
The receivable turnover ratio quantifies a company's ability to collect liabilities/debts. It helps investors gauge the efficiency of a company's collection and credit policies.
A high ratio value indicates an efficient and effective credit policy, and a low ratio indicates a debt collection problem.
The way to read the receivables turnover ratio is as follows. Assume that a company has a receivables turnover ratio of 10. We say that "the company turns over its receivables 10 times during the year." In other words, on average the company collects its outstanding receivables 10 times per year.
Learn More
You may also be interested in these CLDX related companies
CLDX News
$CLDX the call premiums didn't just collapse after Wednesday, thats all I need to know
about 2 days ago by GreatWhiteHype
about 2 days ago by GreatWhiteHype
@NHStocktrdr $CLDX this is a good long term stock. and you right about the big pipeline! I'm a buyer at these levels to average in!
about 2 days ago by BiopharmaPro
about 2 days ago by BiopharmaPro
$CLDX My exit plan here..between $9 and $12. 22,000 shares and holding.Don't care about the BS moves.Looking for the real $$ and we got pipe
about 2 days ago by NHStocktrdr
about 2 days ago by NHStocktrdr
RT @TTGCapital $CLDX close green, nice price axn eod, i'm bullish on this one as you all know.Bullish here to.We'll see a triple in due time
about 2 days ago by NHStocktrdr
about 2 days ago by NHStocktrdr
WSJ article on $CLDX results doesn't say anything new but might bring attention to the name http://stks.co/3yiq
about 4 days ago by illinijill
about 4 days ago by illinijill
$CLDX Upside Blowoff - 15 Minute Down Reversal - Red bar after 6 higher highs and higher lows
about 4 days ago by TradeIdeasQuant
about 4 days ago by TradeIdeasQuant
@low_level_owl i give up with $CLDX lol. just az long az it's under $3 or over $5 i'm happy camper. investorz don't know which way 2 go here
about 4 days ago by johnkelly
about 4 days ago by johnkelly
RT @chesty1 $CLDX @johnkelly People need to stop selling, we'd be in 5's by now lol
about 4 days ago by johnkelly
about 4 days ago by johnkelly
$CLDX @johnkelly People need to stop selling, we'd be in 5's by now
about 4 days ago by chesty1
about 4 days ago by chesty1
$CLDX price axn post data release is telling, this is a longer term buy and hold Baker Brothers style
about 4 days ago by TTGCapital
about 4 days ago by TTGCapital
i bet they hold $CLDX between $4.20-$4.30 till June options expire now
about 4 days ago by johnkelly
about 4 days ago by johnkelly
$CLDX To me this stock seems like a prime example of why some people SHOULDN'T dabble in Bio stocks.
about 4 days ago by chesty1
about 4 days ago by chesty1
$CLDX so after all that we're right back where we started? unbeeleevable they're gunna #$%$% me on my options
about 4 days ago by johnkelly
about 4 days ago by johnkelly
Pre-Open Movers 5/24: (P) (HPQ) (PVH) Higher; (NTAP) (MTGE) (TIF) Lower (more...)
May 24, 9:31AM Street Insider
May 24, 9:31AM Street Insider
After-Hours Movers 05/23: (P) (HPQ) (PVH) Higher; (MNOV) (NTAP) (CLDX) Lower
May 23, 5:48PM Street Insider
May 23, 5:48PM Street Insider
Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
May 23, 4:05PM Street Insider
May 23, 4:05PM Street Insider
Celldex (CLDX) volatility up into conference call to announce EMERGE results
May 23, 12:24PM Street Insider
May 23, 12:24PM Street Insider
Celldex Therapeutics to Host Call to Announce Topline Results from the EMERGE Study in Advanced Breast Cancer
May 18, 10:30AM Business Wire
May 18, 10:30AM Business Wire
Celldex Announces Plans to Release Topline Results from the EMERGE Study in Advanced Breast Cancer
May 01, 7:00AM Business Wire
May 01, 7:00AM Business Wire
Celldex Therapeutics to Host Corporate 2011 Year-End and 2012 Objectives Update Call
Feb 29, 3:00PM Business Wire
Feb 29, 3:00PM Business Wire
Celldex Therapeutics to Present at the Citi 2012 Global Health Care Conference
Feb 24, 10:30AM Business Wire
Feb 24, 10:30AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CLDX | 4.50 | +0.02 | +0.45% | 257.22M |
| CLDT | 12.92 | -0.18 | -1.37% | 178.94M |
| CLD | 15.79 | +0.06 | +0.38% | 961.93M |
| CLCT | 14.43 | +0.05 | +0.35% | 116.88M |
| CLC | 49.40 | -0.34 | -0.68% | 2.483B |
| CL | 98.80 | -0.33 | -0.33% | 47.38B |
| CGEN | 3.80 | -0.25 | -6.17% | 131.90M |
| CGA | 3.37 | +0.04 | +1.20% | 90.79M |
| CFR | 57.51 | +0.00 | +0.00% | 3.525B |
| CFP | 5.43 | +0.01 | +0.18% |